Artemis Investment Management LLP grew its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 75.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 56,163 shares of the company’s stock after buying an additional 24,216 shares during the quarter. Artemis Investment Management LLP’s holdings in Johnson & Johnson were worth $11,623,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after buying an additional 956,239 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after purchasing an additional 835,146 shares during the period. Legal & General Group Plc lifted its position in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock worth $3,606,431,000 after purchasing an additional 532,790 shares during the period. Finally, Amundi lifted its position in Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after acquiring an additional 2,163,838 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Trading Down 1.3%
NYSE JNJ opened at $224.15 on Tuesday. The stock has a market capitalization of $539.57 billion, a PE ratio of 25.91, a price-to-earnings-growth ratio of 2.23 and a beta of 0.27. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71. The firm has a 50 day moving average of $238.83 and a two-hundred day moving average of $219.90.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson’s payout ratio is currently 60.12%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on JNJ shares. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Wolfe Research increased their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. HSBC raised their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $252.48.
Get Our Latest Report on Johnson & Johnson
Key Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: FDA wins and regulatory progress could boost future revenue for JNJ’s rare‑disease and schizophrenia programs; the article discusses how investors may respond to those approvals. How Investors May Respond To Johnson & Johnson (JNJ) New FDA Wins In Rare Disease And Schizophrenia
- Positive Sentiment: JNJ’s CAPLYTA (lumateperone) ranked highest in a network meta‑analysis for adjunctive MDD efficacy and showed no weight gain versus placebo — a favorable positioning for psychiatry sales and prescribing. CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments
- Positive Sentiment: FDA accepted a protocol amendment for the NANORAY‑312 Phase 3 head & neck cancer trial sponsored by JNJ (Nanobiotix program) — regulatory acceptance reduces an execution risk for a partnered oncology asset. Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
- Positive Sentiment: A J&J study supports use of Abiomed’s Impella 5.5 in non‑shock, high‑risk patients, which may help device adoption and hospital use cases relevant to JNJ’s devices/solutions exposure. Johnson & Johnson study backs Abiomed Impella 5.5 in non-shock, high-risk patients
- Neutral Sentiment: Wall Street analysts remain moderately optimistic on JNJ after recent performance — supportive but not a catalyst by itself. Are Wall Street Analysts Bullish on Johnson & Johnson Stock?
- Neutral Sentiment: Investor letters and coverage (Baron/InsiderMonkey pieces) argue JNJ’s accelerating growth justifies a higher multiple — positive for medium‑term thesis but highlights valuation sensitivity. Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple
- Negative Sentiment: Sector dynamics: AbbVie’s strong Q1 results and raised guidance have lifted ABBV shares, which can divert investor funds within the healthcare group and pressure JNJ’s relative performance today. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
